LENZ Therapeutics (LENZ) vs Unicycive Therapeutics (UNCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Unicycive Therapeutics (UNCY) has outperformed LENZ Therapeutics (LENZ) over the past year, losing 14.7% versus a loss of 92.7%. Over five years, UNCY leads with a -85.1% price change compared with -96.1% for LENZ. LENZ Therapeutics is the larger company by market cap ($114.2 million vs $113.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LENZ | UNCY |
|---|---|---|
| Share price | $3.64 | $4.13 |
| Market cap | $114.24M | $113.13M |
| 1-day change | +3.00% | +1.47% |
| YTD return | -77.94% | -29.46% |
| 1-year return | -92.74% | -14.68% |
| 5-year return | -96.05% | -85.06% |
| Forward P/E | — | 2.45 |
| EPS (TTM) | $-4.13 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $46.75 | $8.74 |
| 52-week low | $3.35 | $3.93 |
| Distance from 52-week high | -92.22% | -52.75% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +560.07% | +587.65% |
| Average volume | 833.64K | 839.29K |
| Shares outstanding | 31.42M | 27.39M |
| Employees | 152 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- UNCY has outperformed LENZ by 78.1 percentage points over the past year.
About LENZ Therapeutics
LENZ stock →LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 152 employees
About Unicycive Therapeutics
UNCY stock →Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
LENZ vs UNCY FAQ
Which is bigger, LENZ Therapeutics or Unicycive Therapeutics?
LENZ Therapeutics (LENZ) is larger, with a market capitalization of $114.24M compared with $113.13M for Unicycive Therapeutics (UNCY).
Which stock has performed better over the past year, LENZ or UNCY?
UNCY returned -14.68% over the past 12 months, compared with -92.74% for LENZ (price return, excluding dividends). Past performance does not predict future results.
Are LENZ Therapeutics and Unicycive Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for LENZ Therapeutics and Biotechnology: Pharmaceutical Preparations for Unicycive Therapeutics.